Multimodal treatment strategies for locally advanced rectal cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 4, 2012, Pages 481-494

  Weber, Georg F ^a   Rosenberg, Robert ^b   Murphy, Janet E ^a   Büschenfelde, Christian Meyer Zum ^c   Friess, Helmut ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Cantonal Hospital Baden   (Switzerland)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

adjuvant therapy; locally advanced rectal cancer; multimodal treatment strategies; neoadjuvant therapy; prognostic factors; quality of life; staging; surgery

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CARCINOMATOSIS; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; ILEOSTOMY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PELVIS ABSCESS; PELVIS EXENTERATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; QUALITY OF LIFE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR PERFORATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; WOUND HEALING IMPAIRMENT;

COMBINED MODALITY THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RECTAL NEOPLASMS;

EID: 84859801603     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.3     Document Type: Review

References (128)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Greene, FL, Stewart, AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann. Surg. 236, 416-421; discussion 421 (2002).
3. Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: An analysis. J. Clin. Oncol. 22, 1778-1784 (2004). (Pubitemid 41095167)
4. Dekker JW, Peeters KC, Putter H et al. Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification. Eur. J. Surg. Oncol. 36, 1180-1186 (2010).
5. Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol. Clin. North Am. 31, 827-839 (2002). (Pubitemid 35365015)
6. Bipat S, Glas, AS, Slors FJ et al. Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - A meta-Analysis. Radiology 232, 773-783 (2004). (Pubitemid 39100263)
7. Beets-Tan RG, Beets GL, Vliegen RF et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357, 497-504 (2001). (Pubitemid 32173585)
8. Bissett IP, Fernando CC, Hough DM et al. Identification of the fascia propria by magnetic resonance imaging and its relevance to preoperative assessment of rectal cancer. Dis. Colon Rectum 44, 259-265 (2001). (Pubitemid 32173776)
9. Schaffzin DM, Wong WD. Endorectal ultrasound in the preoperative evaluation of rectal cancer. Clin. Colorectal Cancer 4, 124-132 (2004). (Pubitemid 39199252)
10. Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: The current role of MRI. Eur. Radiol. 17, 379-389 (2007). (Pubitemid 46140309)
11. Kim HJ, Wong WD. Role of endorectal ultrasound in the conservative management of rectal cancers. Semin. Surg. Oncol. 19, 358-366 (2000). (Pubitemid 32186926)
12. Lahaye MJ, Engelen SM, Nelemans PJ et al. Imaging for predicting the risk factors - The circumferential resection margin and nodal disease - Of local recurrence in rectal cancer: A meta-Analysis. Semin. Ultrasound CT MR 26, 259-268 (2005). (Pubitemid 41111583)
13. Huh JW, Park YA, Jung EJ et al. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J. Am. Coll. Surg. 207, 7-12 (2008).
14. Kagda FH, Nyam DC, Ho YH et al. Surgery may be curative for patients with a localized perforation of rectal carcinoma. Br. J. Surg. 86, 1448-1450 (1999). (Pubitemid 29525178)
15. Guillem JG, Puig-La Calle JJ, Akhurst T et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis. Colon Rectum 43, 18-24 (2000). (Pubitemid 30056657)
16. Rosenberg R, Herrmann K, Gertler R et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int. J. Colorectal Dis. 24, 191-200 (2009).
17. Moore HG, Shia J, Klimstra DS et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-Term outcome. Ann. Surg. Oncol. 11, 955-961 (2004). (Pubitemid 40486660)
18. Nahas CS, Akhurst T, Yeung H et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann. Surg. Oncol. 15, 704-711 (2008).
19. Compton C, Fenoglio-Preiser CM, Pettigrew N et al. American Joint Committee on cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88, 1739-1757 (2000). (Pubitemid 30183160)
20. Krasna MJ, Flancbaum L, Cody RP et al. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61, 1018-1023 (1988). (Pubitemid 18058618)
21. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J. Clin. Oncol. 13, 2936-2943 (1995).
22. Wanebo HJ, Rao B, Pinsky CM et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Med. 299, 448-451 (1978). (Pubitemid 9011330)
23. Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann. Surg. 199, 375-382 (1984).
24. Nagtegaal ID, Van De Velde CJ, Van Der Worp E et al. Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J. Clin. Oncol. 20, 1729-1734 (2002). (Pubitemid 34273260)
25. Compton CC. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod. Pathol. 16, 376-388 (2003). (Pubitemid 36443987)
26. Heald RJ, Moran BJ, Ryall RD et al. Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978-1997. Arch. Surg. 133, 894-899 (1998). (Pubitemid 28374285)
27. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
28. Berger AC, Sigurdson ER, LeVoyer T et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J. Clin. Oncol. 23, 8706-8712 (2005). (Pubitemid 46211514)
29. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 21, 2912-2919 (2003). (Pubitemid 46621841)
30. Stocchi L, Nelson H, Sargent DJ et al. Impact of surgical and pathologic variables in rectal cancer: A United States community and cooperative group report. J. Clin. Oncol. 19, 3895-3902 (2001). (Pubitemid 32880068)
31. Swanson RS, Compton CC, Stewart AK et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann. Surg. Oncol. 10, 65-71 (2003).
32. Tepper JE, O'Connell MJ, Niedzwiecki D et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J. Clin. Oncol. 19, 157-163 (2001). (Pubitemid 32063492)
33. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 54, 295-308 (2004). (Pubitemid 40073988)
34. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 21, 241-250 (2003). (Pubitemid 46606152)
35. Diep CB, Thorstensen L, Meling GI et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J. Clin. Oncol. 21, 820-829 (2003). (Pubitemid 46606441)
36. Galizia G, Lieto E, Ferraraccio F et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin. Cancer Res. 10, 3490-3499 (2004). (Pubitemid 38685457)
37. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006). (Pubitemid 44498003)
38. Gertler R, Rosenberg R, Stricker D et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J. Clin. Oncol. 22, 1807-1814 (2004). (Pubitemid 41095170)
39. Kahlenberg MS, Sullivan JM, Witmer DD et al. Molecular prognostics in colorectal cancer. Surg. Oncol. 12, 173-186 (2003). (Pubitemid 37083579)
40. Klump B, Nehls O, Okech T et al. Molecular lesions in colorectal cancer: Impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 19, 23-42 (2004). (Pubitemid 38088282)
41. Nehls O, Okech T, Hsieh CJ et al. Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 61, 85-91 (2005). (Pubitemid 40039109)
42. Nehls O, Okech T, Hsieh CJ et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: Major prognostic impact of proapoptotic BAX. Br. J. Cancer 96, 1409-1418 (2007). (Pubitemid 46685789)
43. Parc Y, Gueroult S, Mourra N et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 53, 371-375 (2004). (Pubitemid 38241332)
44. Peng J, Lu JJ, Zhu J et al. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 14, 54-61 (2008).
45. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-Analysis. J. Clin. Oncol. 22, 529-536 (2004). (Pubitemid 41079782)
46. Shrout J, Yousefzadeh M, Dodd A et al. Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. Br. J. Cancer 98, 1999-2005 (2008). (Pubitemid 351821564)
47. Sinicrope FA, Rego RL, Okumura K et al. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin. Cancer Res. 14, 5810-5818 (2008).
48. French AJ, Sargent DJ, Burgart LJ et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res. 14, 3408-3415 (2008).
49. Johnson SM, Gulhati P, Rampy BA et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J. Am. Coll. Surg. 210, 767-778 (2010).
50. Larsson A, Johansson ME, Wangefjord S et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br. J. Cancer 105, 666-672 (2011).
51. Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C et al. EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. Int. J. Cancer 128, 2938-2946 (2011).
52. Erben P, Strobel P, Horisberger K et al. KRAS and BRAF Mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, 1032-1038 (2011).
53. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6, e17745 (2011).
54. Nishida N, Yokobori T, Mimori K et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int. J. Oncol. 38, 1437-1443 (2011).
55. Borowski DW, Kelly SB, Bradburn DM et al. Impact of surgeon volume and specialization on short-Term outcomes in colorectal cancer surgery. Br. J. Surg. 94, 880-889 (2007). (Pubitemid 47051214)
56. Hodgson DC, Zhang W, Zaslavsky AM et al. Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J. Natl Cancer Inst. 95, 708-716 (2003). (Pubitemid 36665498)
57. Meyerhardt JA, Tepper JE, Niedzwiecki D et al. Impact of hospital procedure volume on surgical operation and long-Term outcomes in high-risk curatively resected rectal cancer: Findings from the Intergroup 0114 Study. J. Clin. Oncol. 22, 166-174 (2004). (Pubitemid 41095129)
58. Renzulli P, Lowy A, Maibach R et al. The influence of the surgeon's and the hospital's caseload on survival and local recurrence after colorectal cancer surgery. Surgery 139, 296-304 (2006).
59. Schrag D, Cramer LD, Bach PB et al. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 284, 3028-3035 (2000). (Pubitemid 32014740)
60. Schrag D, Panageas KS, Riedel E et al. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann. Surg. 236, 583-592 (2002). (Pubitemid 35246890)
61. Hermanek P. Impact of surgeon's technique on outcome after treatment of rectal carcinoma. Dis. Colon Rectum 42, 559-562 (1999). (Pubitemid 29228398)
62. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J. Clin. Oncol. 26, 303-312 (2008).
63. Guillem JG, Chessin DB, Cohen AM et al. Long-Term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann. Surg. 241, 829-836; discussion 836-838 (2005).
64. Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693-701 (2007). (Pubitemid 350035641)
65. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336, 980-987 (1997).
66. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
67. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-Term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 93, 1215-1223 (2006). (Pubitemid 44547018)
68. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J. Clin. Oncol. 24, 4620-4625 (2006). (Pubitemid 46630960)
69. Larsen SG, Wiig JN, Emblemsvaag HL et al. Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-Adjuvant downstaging. Colorectal Dis. 11, 759-767 (2009).
70. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 373, 811-820 (2009).
71. Rosenberg R, Engel J, Bruns C et al. The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann. Surg. 251, 1070-1078 (2010).
72. Rodel C, Liersch T, Hermann RM et al. Multicenter Phase II trial of chemoradiation with oxaliplatin for rectal cancer. J. Clin. Oncol. 25, 110-117 (2007). (Pubitemid 350003058)
73. Hofheinz R, Wenz FK, Post S et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-Term results of a randomized, Phase III trial. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2011 (Abstract 3504).
74. Roedel C, Becker H, Fietkau R et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized Phase III trial. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2011 (Abstract LBA3505).
75. Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized Phase III trial. J. Clin. Oncol. 29(20), 2773-2780 (2011).
76. Gérard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the Phase III trial ACCORD 12/0405-Prodige 2. J. Clin. Oncol. 28(10), 1638-1644 (2010).
77. Roh MS, Yothers GA, O'Connell MJ et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2011 (Abstract 3503).
78. Lim SB, Choi HS, Jeong SY et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann. Surg. 248, 243-251 (2008).
79. Valentini V, van Stiphout RG, Lammering G et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J. Clin. Oncol. 29, 3163-3172 (2011).
80. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst. Rev. CD006041 (2009).
81. Hosein PJ, Rocha-Lima CM. Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin. Colorectal Cancer 7, 369-375 (2008).
82. Martling AL, Holm T, Rutqvist LE et al. Effect of a surgical training programme on outcome of rectal cancer in the county of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 356, 93-96 (2000). (Pubitemid 30438509)
83. Enker WE, Thaler HT, Cranor ML et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J. Am. Coll. Surg. 181, 335-346 (1995).
84. Nesbakken A, Nygaard K, Westerheim O et al. Local recurrence after mesorectal excision for rectal cancer. Eur. J. Surg. Oncol. 28, 126-134 (2002). (Pubitemid 35023653)
85. Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br. J. Surg. 89, 327-334 (2002). (Pubitemid 34227032)
86. McCall JL, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. Int. J. Colorectal Dis. 10, 126-132 (1995).
87. Arbman G, Nilsson E Hallbook O et al. Local recurrence following total mesorectal excision for rectal cancer. Br. J. Surg. 83, 375-379 (1996). (Pubitemid 26083175)
88. Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br. J. Surg. 86, 379-384 (1999). (Pubitemid 29145927)
89. Visser O, Bakx R, Zoetmulder FA et al. The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: A population-based study in Greater Amsterdam. J. Surg. Oncol. 95, 447-454 (2007). (Pubitemid 46709387)
90. Beddy D, Hyland JM, Winter DC et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann. Surg. Oncol. 15, 3471-3477 (2008).
91. Huh JW, Lim SW, Kim HR et al. Effects of postoperative adjuvant radiotherapy on recurrence and survival in stage III rectal cancer. J. Gastrointest. Surg. 15, 963-970 (2011).
92. Krempien R, Roeder F, Oertel S et al. Long-Term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 1143-1151 (2006). (Pubitemid 44633503)
93. Szynglarewicz B, Matkowski R, Maciejczyk A et al. Combined-modality therapy with sphincter-preserving total mesorectal excision for locally advanced rectal cancer: Patient's age and long-Term outcome. J. Gastrointestin. Liver Dis. 17, 49-52 (2008). (Pubitemid 351568874)
94. Veenhof AA, Kropman RH, Engel AF et al. Preoperative radiation therapy for locally advanced rectal cancer: A comparison between two different time intervals to surgery. Int. J. Colorectal Dis. 22, 507-513 (2007). (Pubitemid 46488055)
95. Izbicki JR, Hosch SB, Knoefel WT et al. Extended resections are beneficial for patients with locally advanced colorectal cancer. Dis. Colon Rectum 38, 1251-1256 (1995).
96. Sagar PM. Extended surgery for local recurrence and advanced rectal cancer. Colorectal Dis. 8(Suppl. 3), 43-46 (2006).
97. Wang JP, Song XM. Extended resection for locally advanced colorectal cancer. Chin. Med. J. (Engl.) 119, 1675-1676 (2006).
98. Bokey EL, Ojerskog B, Chapuis PH et al. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: Role of total anatomical dissection. Br. J. Surg. 86, 1164-1170 (1999). (Pubitemid 29427833)
99. Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J. Surg. 16, 848-857 (1992).
100. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - The clue to pelvic recurrence? Br. J. Surg. 69, 613-616 (1982). (Pubitemid 12038080)
101. Chessin DB, Guillem JG. Abdominoperineal resection for rectal cancer: Historic perspective and current issues. Surg. Oncol. Clin. N. Am. 14, 569-586, vii (2005). (Pubitemid 40835801)
102. Schultheis KH, Ruckriegel S, Gebhardt C. [Multivisceral resection of advanced colorectal cancer]. Langenbecks Arch. Chir. 379, 20-25 (1994). (Pubitemid 24049532)
103. Gebhardt C, Meyer W, Ruckriegel S et al. Multivisceral resection of advanced colorectal carcinoma. Langenbecks Arch. Surg. 384, 194-199 (1999). (Pubitemid 29227312)
104. Lehnert T, Methner M, Pollok A et al. Multivisceral resection for locally advanced primary colon and rectal cancer: An analysis of prognostic factors in 201 patients. Ann. Surg. 235, 217-225 (2002). (Pubitemid 34111950)
105. Moriya Y, Akasu T, Fujita S et al. Aggressive surgical treatment for patients with T4 rectal cancer. Colorectal Dis. 5, 427-431 (2003). (Pubitemid 37080648)
106. Takeuchi H, Ueo H, Haraoka M et al. Surgical results of total pelvic exenteration for locally advanced colorectal adenocarcinoma. Hepatogastroenterology 52, 90-93 (2005). (Pubitemid 40282638)
107. Visokai V, Lipska L, Bergmann P et al. Multiorgan resections for advanced colorectal cancer. Anticancer Res. 26, 3183-3186 (2006). (Pubitemid 44161820)
108. Derici H, Unalp HR, Kamer E et al. Multivisceral resections for locally advanced rectal cancer. Colorectal Dis. 10, 453-459 (2008). (Pubitemid 351682172)
109. Sokmen S, Terzi C, Unek T et al. Multivisceral resections for primary advanced rectal cancer. Int. J. Colorectal Dis. 14, 282-285 (1999). (Pubitemid 30085261)
110. Bakx R, Visser O, Josso J et al. Management of recurrent rectal cancer: A population based study in greater Amsterdam. World J. Gastroenterol. 14, 6018-6023 (2008).
111. Chen HS, Sheen-Chen SM. Total pelvic exenteration for primary local advanced colorectal cancer. World J. Surg. 25, 1546-1549 (2001).
112. Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J. Am. Coll. Surg. 190, 78-83 (2000). (Pubitemid 30020579)
113. Shirouzu K, Isomoto H, Kakegawa T. Total pelvic exenteration for locally advanced colorectal carcinoma. Br. J. Surg. 83, 32-35 (1996). (Pubitemid 26022273)
114. Vermaas M, Ferenschild FT, Verhoef C et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur. J. Surg. Oncol. 33, 452-458 (2007). (Pubitemid 46586088)
115. Huser N, Michalski CW, Erkan M et al. Systematic review and meta-Analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann. Surg. 248, 52-60 (2008).
116. Fazio VW, Zutshi M, Remzi FH et al. A randomized multicenter trial to compare long-Term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann. Surg. 246, 481-488; discussion 488-490 (2007).
117. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21, 3737-3743 (2003). (Pubitemid 46606227)
118. Glehen O, Cotte E, Schreiber V et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br. J. Surg. 91, 747-754 (2004). (Pubitemid 38746144)
119. Shen P, Hawksworth J, Lovato J et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann. Surg. Oncol. 11, 178-186 (2004). (Pubitemid 40486793)
120. Verwaal VJ, van Tinteren H, van Ruth S et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br. J. Surg. 91, 739-746 (2004). (Pubitemid 38746143)
121. Abdelrazeq AS, Scott N, Thorn C et al. The impact of spontaneous tumour perforation on outcome following colon cancer surgery. Colorectal Dis. 10, 775-780 (2008).
122. Wu ZY, Wan J, Zhao G et al. Risk factors for local recurrence of middle and lower rectal carcinoma after curative resection. World J. Gastroenterol. 14, 4805-4809 (2008).
123. McKenzie SP, Barnes SL, Schwartz RW. An update on the surgical management of rectal cancer. Curr. Surg. 62, 407-411 (2005). (Pubitemid 40862390)
124. Hassan I, Cima RR. Quality of life after rectal resection and multimodality therapy. J. Surg. Oncol. 96, 684-692 (2007).
125. Pachler J, Wille-Jorgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst. Rev. CD004323 (2005).
126. Palmer G, Martling A, Lagergren P et al. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann. Surg. Oncol. 15, 3109-3117 (2008).
127. Perez Lara FJ, Navarro Pinero A, de la Fuente Perucho A. Study of factors related to quality of life in patients with locally advanced rectal cancer. Rev. Esp. Enferm. Dig. 96, 746-757 (2004). (Pubitemid 40214513)
128. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002). (Pubitemid 34976022)